Cornelius Clancy to Anti-Bacterial Agents
This is a "connection" page, showing publications Cornelius Clancy has written about Anti-Bacterial Agents.
Connection Strength
0.995
-
Antibiotic Consumption and Stewardship at a Hospital outside of an Early Coronavirus Disease 2019 Epicenter. Antimicrob Agents Chemother. 2020 10 20; 64(11).
Score: 0.181
-
Colistin Does Not Potentiate Ceftazidime-Avibactam Killing of Carbapenem-Resistant Enterobacteriaceae In Vitro or Suppress Emergence of Ceftazidime-Avibactam Resistance. Antimicrob Agents Chemother. 2018 08; 62(8).
Score: 0.155
-
Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia. Antimicrob Agents Chemother. 2017 08; 61(8).
Score: 0.144
-
In Vitro Selection of Meropenem Resistance among Ceftazidime-Avibactam-Resistant, Meropenem-Susceptible Klebsiella pneumoniae Isolates with Variant KPC-3 Carbapenemases. Antimicrob Agents Chemother. 2017 05; 61(5).
Score: 0.142
-
Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne blaKPC-3 Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections. Antimicrob Agents Chemother. 2017 03; 61(3).
Score: 0.140
-
Coronavirus Disease 2019, Superinfections, and Antimicrobial Development: What Can We Expect? Clin Infect Dis. 2020 12 17; 71(10):2736-2743.
Score: 0.046
-
Prevalence of Inappropriate Antibiotic Prescribing in Primary Care Clinics within a Veterans Affairs Health Care System. Antimicrob Agents Chemother. 2018 08; 62(8).
Score: 0.039
-
Identifying Spectra of Activity and Therapeutic Niches for Ceftazidime-Avibactam and Imipenem-Relebactam against Carbapenem-Resistant Enterobacteriaceae. Antimicrob Agents Chemother. 2017 09; 61(9).
Score: 0.036
-
Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: Clinical Effectiveness and Evolution of Resistance. Clin Infect Dis. 2017 07 01; 65(1):110-120.
Score: 0.036
-
Gram-Negative Bacterial Infections: Research Priorities, Accomplishments, and Future Directions of the Antibacterial Resistance Leadership Group. Clin Infect Dis. 2017 Mar 15; 64(suppl_1):S30-S35.
Score: 0.035
-
Key considerations on the potential impacts of the COVID-19 pandemic on antimicrobial resistance research and surveillance. Trans R Soc Trop Med Hyg. 2021 10 01; 115(10):1122-1129.
Score: 0.012
-
Antimicrobial resistance research in a post-pandemic world: Insights on antimicrobial resistance research in the COVID-19 pandemic. J Glob Antimicrob Resist. 2021 06; 25:5-7.
Score: 0.012
-
Verification of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Susceptibility Testing Methods against Carbapenem-Resistant Enterobacteriaceae and Pseudomonas aeruginosa. J Clin Microbiol. 2018 02; 56(2).
Score: 0.009
-
Mutations in blaKPC-3 That Confer Ceftazidime-Avibactam Resistance Encode Novel KPC-3 Variants That Function as Extended-Spectrum ß-Lactamases. Antimicrob Agents Chemother. 2017 05; 61(5).
Score: 0.009